| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_751562df05f1831baef905641425c407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb258be6a48fd6826b8c923ea4234dff |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6937
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 |
| filingDate |
2020-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01f3a3faeac4a944329f97599802c761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90d3a978c988018e0bccd6125a0f1e3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39e65dcc4361a65073e14fb1f3328d52 |
| publicationDate |
2021-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021092172-A1 |
| titleOfInvention |
Functionally modified maytansinoids and compositions and methods of use thereof |
| abstract |
Radiosensitizer prodrugs and formulations and methods of use thereof are provided. Typically, the radiosensitizer prodrug is an analog of a radiosensitizer parent compound having one or more S-nitrosothiol moieties. Typically, the S-N bond of the S-nitrosothiol moiety can be cleaved by radiation during radiotherapy, releasing the parent compound and nitric oxide. One or preferably both the parent compound and the nitric oxide can contribute to death of tumor cells exposed to radiotherapy. Nanoparticle formulations for delivery of the prodrug, and methods of using them in combination with radiotherapy to treat tumors and cancer are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023147552-A1 |
| priorityDate |
2019-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |